Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders

NEXT STORY
World Telehealth Initiative Receives Investment from Intel Corporation to Expand Access to Medical Care in Vulnerable Communities Around the World
PREV STORY
Philips, BioIntelliSense and University of Colorado receive U.S. Department of Defense funding for early COVID-19 detection
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

author_avatar
NASDAQ Market News

Precision Medicine Market Size & Share 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research

author_avatar
NASDAQ Market News

Novel late-stage colorectal cancer treatment proves effective in preclinical models

author_avatar
NASDAQ Market News